Clinical Trial Update: LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma [Phase 1]

View source ↗

Summary

Update on a Phase 1 clinical trial of the LMB-2 immunotoxin in young patients with relapsed or refractory leukemia or lymphoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• LMB-2

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED